Avidity Biosciences Inc (RNA) Actualités

Form 8-K - Current report

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights PR Newswire SAN DIEGO...

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First...

Form 8-K - Current report

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC...

Form 144 - Report of proposed sale of securities

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Sept. 25, 2024 SAN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities